Bristol-Myers Squibb Co. (BMY) posted loss for the fourth-quarter 2017, compared to profit in the prior year, reflecting impact from U.S. tax reform. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. It also announced positive results for its Opdivo and Yervoy cancer drug combination in a late-stage clinical trial.
from RTT - Earnings http://ift.tt/2FNwqHr
via IFTTT
No comments:
Post a Comment